Join        Login             Stock Quote

Celgene (CELG): Long-Term Buy, Short-Term Wait

 January 08, 2013 05:47 PM

(By Rich Bieglmeier) Celgene (CELG) is the beneficiary of not one, but two upgrades today. RBC Capital moved its recommendation from "sector perform" to "outperform" while upping their price target from $90 to $100.

Piper Jaffray also thinks the biotech is a triple digit stock, putting a potential price tag of $110 on shares on their fresh "overweight" rating, hiked from "neutral." The pair of recommendation changes implies as-we-type upside of 9.9% and 20.1%, respectively.

While the two firms might eventually be correct, CELG's charts show a stock that's overbought and due for a correction. Shares are currently six standard deviations of 20-day volatility above the 20-day moving average, hardly a position a stock can withstand for an extended period of time. Celgene is as stretched out as far as we have ever seen from this perspective. Additionally, CELG's relative strength reading is at a 12 month high at 81.65, another reading that usually won't last long.

[Related -Celgene Corporation (NASDAQ:CELG): Why Should You Invest In Celgene In 2014?]

A return trip to $84 would put the stock back into a more normal trading range.

Shares are sharply higher today and to start the week, as well. The company told a J.P. Morgan Healthcare Conference on Monday that the plan is to double sales to $12 billion by 2017 thanks to efforts to find new therapies and expand uses for older drugs. CELG has gained 11.53% in the first two trading days of the week.

[Related -Celgene Corporation (CELG): How Q3 Earnings Will Fare?]

Relative to its peer group, Celgene is fairly priced according to two of iStock's favorite metrics. Based on  price-to-sales (P/S) CELG is a little underpriced at 6.79 P/S compared to the industry's 8.29. Meanwhile, the biotech trailing twelve month P/E of 25.20 is marked versus the group's 21.51.

Although we suspect shares are getting a little ahead of themselves and vulnerable to profit taking, relative to its P/E and P/S history, CELG has headroom to move higher to meet its five year averages.

As we mentioned already, the market has priced shares at 25.20 times trailing twelve month earnings per share which is 20% lower than the fiver year average of 31.71. We see a similar markdown on a P/S basis as the five-years average stands at 8.9 matched against today's  6.79.  Getting back to the five year averages would put CELG closer to Piper Jaffray's estimate than RBC.

Overall, Celgene (CELG) would have to grow sales by roughly 18% a year during the next four years to hit their goal of doubling revenue, which is actually less than Wall Street 3-5 year growth estimate 22%. CELG is attractive for long-term investors; however, patience might payoff in the short-term as the stock price is stretched to its upper limits in our view.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Trying To Beat The Market Is A Fool's Errand
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.